Want to see OSTX full AI Analyst Report?
OSTX Stock Chart & Stats
$1.68
$0.01(0.66%)
At close: 4:00 PM EDT
$1.68
$0.01(0.66%)
Day’s Range― - ―
52-Week Range$1.15 - $2.25
Previous Close$1.56
Volume216.20K
Average Volume (3M)833.37K
Market Cap
$66.00M
Enterprise Value$84.28M
Total Cash (Recent Filing)$205.03K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.61
Next Earnings
Nov 13, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding46,805,230
10 Day Avg. Volume1,021,234
30 Day Avg. Volume833,370
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-6.72
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap1.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-224.87
Enterprise Value/Ebitda-2.18
Forecast
1Y Price Target
$8.67Price Target Upside415.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.76
Revenue Forecast (FY)$2.00M
Bulls Say, Bears Say
Bulls Say
Commercialization ReadinessAdding dedicated finance and commercial leadership supports the transition from clinical development toward launch planning. This can improve regulatory coordination, capital allocation, partnership execution, and market preparation for Herlystic over the next several quarters.
Non-Dilutive Funding SupportRefundable tax credits and VAT recoveries provide non-dilutive funding for commercial manufacturing and Phase 3 development. These sources can extend available cash, reduce immediate equity dependence, and support continued advancement of the lead program.
Improved Cash TimingDeferred vendor payments may better align cash outflows with anticipated inflows while clinical and regulatory work continues. This arrangement can ease near-term liquidity pressure and give management additional time to secure funding or advance potential revenue pathways.
Bears Say
No Commercial RevenueThe absence of commercial revenue means OSTX remains dependent on financing, partnerships, or future regulatory success to fund operations. Without product sales, the company has limited internally generated cash and no demonstrated commercial earnings base.
Persistent Cash BurnPersistent operating and free-cash-flow deficits require OSTX to keep raising capital or obtaining other funding to sustain development. Continued cash consumption can constrain trial execution, reduce strategic flexibility, and increase financing pressure before commercialization.
Negative Equity CushionNegative equity indicates an accumulated deficit and a thin capital cushion as losses continue. This weakens balance-sheet resilience, limits flexibility during setbacks, and makes the company more exposed to unfavorable financing terms or funding interruptions.
OS Therapies Incorporated News
OSTX FAQ
What was OS Therapies Incorporated’s price range in the past 12 months?
OS Therapies Incorporated lowest stock price was $1.15 and its highest was $2.25 in the past 12 months.
What is OS Therapies Incorporated’s market cap?
OS Therapies Incorporated’s market cap is $66.00M.
When is OS Therapies Incorporated’s upcoming earnings report date?
OS Therapies Incorporated’s upcoming earnings report date is Nov 13, 2026 which is in 27 days.
How were OS Therapies Incorporated’s earnings last quarter?
OS Therapies Incorporated released its earnings results on Aug 17, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.178 by -$0.022.
Is OS Therapies Incorporated overvalued?
According to Wall Street analysts OS Therapies Incorporated’s price is currently Undervalued.
Does OS Therapies Incorporated pay dividends?
OS Therapies Incorporated does not currently pay dividends.
What is OS Therapies Incorporated’s EPS estimate?
OS Therapies Incorporated’s EPS estimate is -0.14.
How many shares outstanding does OS Therapies Incorporated have?
OS Therapies Incorporated has 46,805,230 shares outstanding.
What happened to OS Therapies Incorporated’s price movement after its last earnings report?
OS Therapies Incorporated reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.178. Following the earnings report the stock price went down -9.259%.
Which hedge fund is a major shareholder of OS Therapies Incorporated?
Currently, no hedge funds are holding shares in OSTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
OS Therapies Incorporated Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.67 (415.87% Upside)
$8.67 (415.87% Upside)
Blogger Sentiment
Bullish
OSTX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 15.9%
Last 30 Days ▲ 15.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.64%
12-Months-Change
Fundamentals
Return on Equity
683.03%
Trailing 12-Months
Asset Growth
-4.01%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
OSTX Stock 12 Month Forecast
Average Price Target
$8.67
▲(415.87% Upside)
Technical Analysis
Ownership Overview
7.90%
Insiders
1.47% Mutual Funds
0.57% Other Institutional Investors
88.06% Public Companies and
Individual Investors